Imaging company raises $26M to develop digital x-ray service, AI-powered cloud software

Nano-X Imaging (Nanox), an imaging technology company based out of Israel, has announced the completion of a funding round worth $26 million. The company has now raised $55 million overall.

This latest funding round was made possible by a new strategic investment from Foxconn, which joins Fujifilm, SK Telecom and other investors in backing the company’s mission to bring digital x-ray capabilities to modern imaging systems. The funding is expected to go toward the continued “development, commercialization and deployment” of the Nanox System, which includes a digital x-ray device (Nanox.Arc) and a cloud-based, AI-powered software solution (Nanox.Cloud).

The Nanox System is designed to be an end-to-end imaging service that assists customers with everything from diagnostic reviews and annotation to AI connectivity and medical billing. Nanox’s goal with these solutions, once they gain the proper regulatory approval, is to work with various governments and health systems to offer a “pay-per-scan” business model.

“We are honored to have Foxconn join other world leaders Fujifilm and SK Telecom in investing in our vision of eradicating cancer,” Ran Poliakine, founder and CEO of Nanox, said in the prepared statement. “Nanox has achieved a technological breakthrough by digitizing traditional x-rays, and now we are ready to take a giant leap forward in making it possible to provide one scan per person, per year, for preventative measures.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.